Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Breast Neoplasms 44Pancreatic Neoplasms 37Carcinoma, Non-Small-Cell Lung 37Triple Negative Breast Neoplasms 28Ovarian Neoplasms 20Fallopian Tube Neoplasms 19Lung Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Neoplasm Metastasis 11Uterine Cervical Neoplasms 8Melanoma 7Inflammatory Breast Neoplasms 7Esophageal Squamous Cell Carcinoma 6Breast Neoplasms, Male 6Stomach Neoplasms 5Cholangiocarcinoma 5Brenner Tumor 5Pancreatic Adenocarcinoma 4Neoplasms 4Esophageal Neoplasms 4Carcinoma, Transitional Cell 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma of Lung 4Adenocarcinoma Of Esophagus 4Urinary Bladder Neoplasms 3Pleural Effusion, Malignant 3Oropharyngeal Neoplasms 3Nasopharyngeal Carcinoma 3Mouth Neoplasms 3Endometrial Neoplasms 3

Interventions

Gemcitabine 7Albumin-Bound Paclitaxel 5Taxes 4Fluorouracil 4dehydroftorafur 3Radiotherapy 3Oxaliplatin 3Radiotherapy, Intensity-Modulated 2Losartan 2Leucovorin 2Irinotecan 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1indusatumab 1X-Rays 1Surgical Procedures, Operative 1Specimen Handling 1S 1 (combination) 1Radiotherapy, Image-Guided 1Radiation 1Pancreatectomy 1Folfox protocol 1Erlotinib Hydrochloride 1Cetuximab 1Capecitabine 1Anesthesia, General 1Anesthesia 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Adenocarcinoma × Taxes × Clear all
NCT05624918 2026-04-08

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Big Ten Cancer Research Consortium

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Active not recruiting
42 enrolled 13 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT02427841 2023-09-06

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

OHSU Knight Cancer Institute

Phase 2 Completed
20 enrolled 17 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT02562716 2022-10-19

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

SWOG Cancer Research Network

Phase 2 Completed
147 enrolled 16 charts
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡